Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Molina Healthcare is a government-sponsored managed care organization serving approximately 5.5 million Medicaid, Medicare, and Marketplace members across 19 states. The company generates revenue through capitated premium payments from state and federal governments, with profitability dependent on managing medical loss ratios (MLR) below premium rates. Recent 60% net income decline reflects elevated medical costs and margin compression in a capital-light, operationally-leveraged business model.
Molina receives fixed monthly capitated premiums from state Medicaid agencies and CMS for each enrolled member. Profitability depends on managing medical costs (MLR) below premium rates, targeting 88-90% MLR in Medicaid. The company earns administrative fees of 8-10% of premiums, with underwriting margin of 1-3% after medical costs. Competitive advantage lies in operational expertise serving complex, low-income populations and established state relationships, though pricing power is limited by government rate-setting. Scale economies exist in claims processing, utilization management, and provider network contracting across 5.5 million members.
Medical Loss Ratio (MLR) performance versus 88-90% target - 100bp MLR change impacts operating margin by ~20-25%
State Medicaid rate adequacy and supplemental payment timing (directed payments, quality incentives)
Membership growth or attrition driven by Medicaid redeterminations post-PHE unwinding
Medicare Advantage Star Ratings affecting bonus payments (currently 3.5-4.0 stars across plans)
State contract wins, losses, or expansions (e.g., Texas STAR+PLUS, California Medi-Cal)
Medicaid redetermination volatility - post-PHE unwinding caused 15-20% membership attrition in 2023-2024, with healthier members disenrolling first (adverse selection risk)
State budget pressures leading to inadequate rate increases relative to 6-8% annual medical cost trend (wage inflation for nurses, specialty drug costs)
Regulatory risk from state contract non-renewals or punitive actions for quality/access deficiencies
Shift toward value-based care and provider risk-sharing reducing managed care margins over time
Competition from larger diversified payers (UnitedHealth, Centene, Elevance) with greater scale and care management capabilities
State RFP losses to competitors offering lower bids or superior quality scores
Provider consolidation increasing negotiating leverage and medical costs
Negative operating cash flow of $-0.5B and FCF of $-0.6B indicate working capital strain or reserve strengthening
Debt/equity of 0.97 limits financial flexibility for M&A or share repurchases
Regulatory capital requirements (RBC 300-400% target) constrain dividend capacity and require $2.5-3.0B in statutory surplus
low to moderate - Revenue is counter-cyclical as Medicaid enrollment increases during recessions when unemployment rises and individuals lose employer coverage. However, state budget pressures during downturns can lead to rate cuts or delayed payments. Medicare and Marketplace segments are less cyclical. Overall, 80% Medicaid exposure provides recession resilience but exposes company to state fiscal health.
Rising rates modestly benefit investment income on $2.5-3.0 billion statutory capital and claims reserves, adding 5-10 cents per share annually per 100bp rate increase. However, higher rates increase discount rate for long-duration medical liabilities and can pressure valuation multiples for low-growth healthcare stocks. Debt/equity of 0.97 means moderate refinancing risk, though most debt is termed out. Net impact is slightly positive for earnings, negative for valuation.
Minimal direct credit exposure - revenue comes from government payers (states, CMS) with minimal default risk. However, state budget crises can delay premium payments or reduce rate adequacy. Provider network stability depends on Molina's ability to pay claims timely (45-50 DCP standard). No meaningful loan portfolio or credit-sensitive revenue.
value - Stock trades at 0.2x P/S and 6.7x EV/EBITDA, well below historical 0.3-0.4x P/S, reflecting distressed valuation after 50% decline. Attracts deep value investors betting on MLR normalization and turnaround from operational issues. Not a growth or dividend stock given 11.7% revenue growth and minimal payout. Requires patience for multi-quarter margin recovery.
high - Stock down 50% over 1 year with -16% 6-month return reflects elevated volatility from quarterly MLR misses and earnings disappointments. Government managed care stocks exhibit high beta (1.2-1.5) to healthcare sector due to binary state contract outcomes and MLR sensitivity. Thin 1.0% net margins amplify earnings volatility from medical cost surprises.